Experimental Drug Shows Positive Results in Mesothelioma Trial

A phase one clinical trial has reported encouraging outcomes for a new drug targeting relapsed mesothelioma, with 67% of patients showing disease control. Published in Nature Communications, the study indicated that patients tolerated the drug well and experienced extended survival compared to standard treatments. Researchers from the University of Vermont led the investigation, which focuses on inhibiting the PRX3 enzyme to induce oxidative stress in tumor cells.